Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a wearable sensor accurately track blood sugar in the ICU?

NCT ID NCT07201155

Knowledge-focused Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well a continuous glucose monitor (CGM) works in critically ill patients with high blood sugar. Researchers placed a small sensor on the skin of 55 ICU patients to measure glucose every 5 minutes for up to 7 days. They compared these readings to standard blood tests to see if the device is accurate enough for ICU use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

55 people

The number who actually took part.

Started

May 2024

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

blood glucose (BG\>180 mg/dL) undergoing intravenous insulin therapy

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria included 1. Age ≥18 years and ≤75 years; 2. Expected ICU stay of at least 3 days; 3. Elevated blood glucose (BG \>180 mg/dL) requiring intravenous insulin therapy; 4. Informed consent obtained from the patient or their legally authorized representative. Exclusion criteria included 1. Severe hepatic failure (Child-Pugh class C) or marked liver dysfunction (total bilirubin ≥50 μmol/L and alanine aminotransferase ≥3 times the upper limit of normal); 2. Uncorrected diabetic ketoacidosis; ability to self-feed; planned magnetic resonance imaging (MRI) examination; 3. Pregnancy or breastfeeding; 4. Extensive skin burns, dermatitis, or severe infections precluding the use of a continuous glucose monitoring system; 5. Severe brain injury, brain death, or moribund state; 6. Deemed unsuitable for study participation by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperglycemia in critically ill patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperglycemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperglycemia in critically ill patients

Contacts and locations

Locations

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, 510000, China